Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders

被引:37
作者
Sargent, Jeremy T. S. [1 ]
Smith, Owen P. [1 ]
机构
[1] Our Ladys Childrens Hosp, Dublin, Ireland
关键词
hypercalcaemia; haematological malignancy; paediatric haematology; therapy; bisphosphonates; HORMONE-RELATED PROTEIN; ACUTE-LYMPHOBLASTIC-LEUKEMIA; KAPPA-B LIGAND; TRANS-RETINOIC ACID; CHRONIC MYELOID-LEUKEMIA; T-CELL LEUKEMIA; PHASE-II TRIAL; RECEPTOR ACTIVATOR; MULTIPLE-MYELOMA; GALLIUM NITRATE;
D O I
10.1111/j.1365-2141.2010.08173.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Hypercalcaemia is a common metabolic complication of malignant disease often requiring emergency intervention. Although it is more frequently associated with solid tumours, malignancy-associated hypercalcaemia (MAH) is seen in a significant number of patients with blood diseases. Its association with myeloma and adult T-cell leukaemia/lymphoma is well recognized but the incidence of hypercalcaemia in other haematological neoplasms, affecting adults and children, is less clearly defined. Haematologists need to be familiar with the clinical manifestations of, the differential diagnosis to be considered and the most effective management strategies that are currently available for MAH. The key components of management of MAH include aggressive rehydration, specific therapy to inhibit bone resorption and, crucially, treatment of the underlying malignancy. Bisphosphonates have revolutionized the management of MAH over the last 20 years, however the elucidation of molecular pathways implicated in MAH is facilitating the development of more targeted approaches to treatment.
引用
收藏
页码:465 / 477
页数:13
相关论文
共 105 条
  • [1] Andiran N, 2006, TURKISH J PEDIATR, V48, P248
  • [2] Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia
    Atula, ST
    Tähtelä, RK
    Nevalainen, JI
    Pylkkänen, LH
    [J]. ACTA ONCOLOGICA, 2003, 42 (07) : 735 - 740
  • [3] ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression
    Baudis, Michael
    Prima, Victor
    Tung, Yoon Han
    Hunger, Stephen P.
    [J]. PEDIATRIC BLOOD & CANCER, 2006, 47 (06) : 757 - 764
  • [4] Beaudreuil J, 1997, CANCER-AM CANCER SOC, V79, P1211, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1211::AID-CNCR21>3.0.CO
  • [5] 2-1
  • [6] Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole
    Bennett, MT
    Sirrs, S
    Yeung, JK
    Smith, CA
    [J]. LEUKEMIA & LYMPHOMA, 2005, 46 (12) : 1829 - 1831
  • [7] BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196
  • [8] A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    Body, JJ
    Facon, T
    Coleman, RE
    Lipton, A
    Geurs, F
    Fan, M
    Holloway, D
    Peterson, MC
    Bekker, P
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1221 - 1228
  • [9] A case of acute lymphoblastic leukemia presenting as severe hypercalcemia
    Buonuomo, PS
    Ruggiero, A
    Piastra, M
    Riccardi, R
    Polidori, G
    Chiaretti, A
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2004, 21 (06) : 475 - 479
  • [10] INCIDENCE OF HYPERCALCEMIA AND MALIGNANT NEOPLASM
    BURT, ME
    BRENNAN, MF
    [J]. ARCHIVES OF SURGERY, 1980, 115 (06) : 704 - 707